CPD's Research Goals:
To enable novel and improved routes to small-molecule targets via new and improved
biocatalysts and integration of reaction and product/(bio)catalyst separation.
To predict the long-term stability of the active ingredient in vials, tablets and vaccines to extend the safety of drugs and vaccines being stored for extended periods with the
aim of new approaches to formulating vaccines.
To establish accelerated and non-accelerated stability testing of pharmaceutical products to enhance the shelf-life of pharmaceutical products and to explore rapid identification of drug product to detect counterfeit, degraded and adulterated drugs.
CPD Current Projects:
Development of environmentally benign (Green Chemistry) routes to small-molecule pharmaceuticals or their intermediates, more specifically development and improvement of
• a biocatalyst or chemocatalyst towards a key synthesis step, or
• a separation and purification step, or
• the integration of reaction with the separation-purification sequence.
Prediction of the propensity of proteins to aggregate, unfold, or dissociate, more specifically
• the use of accelerated tests to probe aggregation, unfolding, or dissociation, or
• design of protein engineering-based protocols to stabilize proteins against stresses stemming from temperature, buffer components, or organic solvents.
Identification of methods for the rapid screening of formulated drug products, more specifically
• rapid identification of drug product to detect degraded, counterfeit, or adulterated drugs.
Development of methods to ensure long-term stability of drug products, especially tablets and vaccines, more specifically
• development of methods for the prediction of the long-term stability of the active ingredient in tablets and vaccines to extend the safety of drugs and vaccines being stored for extended periods
• exploration of new approaches to formulating vaccines based on these stability studies.
Development of better understanding of raw materials quality and its effect on product performance, more specifically
• creation of a raw materials sample library and critical quality attribute variability database
• development of the understanding necessary to improve manufacturability and enhance the prediction of dosage form performance.